Lyumjev ® ▼ (insulin lispro)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Can patients treated with Lyumjev®▼ (insulin lispro) receive COVID-19 vaccines?

The use of vaccines against SARS-CoV-2 in patients treated with Lyumjev has not been studied.

Administration of COVID-19 Vaccines to Patients Receiving Lyumjev

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that has caused the recent COVID-19 pandemic (coronavirus disease 2019, COVID). Recently, vaccines have been developed against SARS-CoV-2 and additional vaccines are expected to be available in the coming months.1-3

SARS-CoV-2 Vaccination With Lyumjev

The use of a SARS-CoV-2 vaccine in patients treated with Lyumjev has not been studied by Eli Lilly and Company.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with Lyumjev should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination.

Possible impact of vaccination on blood glucose concentration

The International Diabetes Federation IDF states that after any vaccination the blood glucose levels might rise for a few days.4

Further resources on COVID-19 Vaccines and Diabetes

For information on COVID-19 vaccines and diabetes, please refer to

For current information on COVID-19 and COVID-19 vaccines in gereral, please refer to the website of


1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237.

2. Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920-1931.

3. COVID-19 vaccines. Centers for Disease Control and Prevention. Updated December 31, 2020. Accessed January 4, 2021.

4. International Diabetes Federation Europe. Diabetes & Coronavirus Vaccination. Accessed April 29, 2021

5. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020.

6. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 04 January 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request